Personalized immunotherapy in cancer precision medicine
With the significant advances in cancer genomics using next-generation sequencing technologies, genomic and molecular profiling-based precision medicine is used as a part of routine clinical test for guiding and selecting the most appropriate treatments for individual cancer patients. Although many...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
China Anti-Cancer Association
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2d8dff79209e45a3b7ae968557deba2c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2d8dff79209e45a3b7ae968557deba2c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2d8dff79209e45a3b7ae968557deba2c2021-11-30T11:27:44ZPersonalized immunotherapy in cancer precision medicine2095-394110.20892/j.issn.2095-3941.2021.0032https://doaj.org/article/2d8dff79209e45a3b7ae968557deba2c2021-11-01T00:00:00Zhttp://www.cancerbiomed.org/index.php/cocr/article/view/1885https://doaj.org/toc/2095-3941With the significant advances in cancer genomics using next-generation sequencing technologies, genomic and molecular profiling-based precision medicine is used as a part of routine clinical test for guiding and selecting the most appropriate treatments for individual cancer patients. Although many molecular-targeted therapies for a number of actionable genomic alterations have been developed, the clinical application of such information is still limited to a small proportion of cancer patients. In this review, we summarize the current status of personalized drug selection based on genomic and molecular profiling and highlight the challenges how we can further utilize the individual genomic information. Cancer immunotherapies, including immune checkpoint inhibitors, would be one of the potential approaches to apply the results of genomic sequencing most effectively. Highly cancer-specific antigens derived from somatic mutations, the so-called neoantigens, occurring in individual cancers have been in focus recently. Cancer immunotherapies, which target neoantigens, could lead to a precise treatment for cancer patients, despite the challenge in accurately predicting neoantigens that can induce cytotoxic T cells in individual patients. Precise prediction of neoantigens should accelerate the development of personalized immunotherapy including cancer vaccines and T-cell receptor-engineered T-cell therapy for a broader range of cancer patients.Kazuma KiyotaniYujiro ToyoshimaYusuke NakamuraChina Anti-Cancer Associationarticlepersonalized medicinecancer precision medicineneoantigenpersonalized immunotherapyimmune checkpoint blockadecancer vaccineadoptive t cell therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Biology & Medicine, Vol 18, Iss 4, Pp 955-965 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
personalized medicine cancer precision medicine neoantigen personalized immunotherapy immune checkpoint blockade cancer vaccine adoptive t cell therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
personalized medicine cancer precision medicine neoantigen personalized immunotherapy immune checkpoint blockade cancer vaccine adoptive t cell therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kazuma Kiyotani Yujiro Toyoshima Yusuke Nakamura Personalized immunotherapy in cancer precision medicine |
| description |
With the significant advances in cancer genomics using next-generation sequencing technologies, genomic and molecular profiling-based precision medicine is used as a part of routine clinical test for guiding and selecting the most appropriate treatments for individual cancer patients. Although many molecular-targeted therapies for a number of actionable genomic alterations have been developed, the clinical application of such information is still limited to a small proportion of cancer patients. In this review, we summarize the current status of personalized drug selection based on genomic and molecular profiling and highlight the challenges how we can further utilize the individual genomic information. Cancer immunotherapies, including immune checkpoint inhibitors, would be one of the potential approaches to apply the results of genomic sequencing most effectively. Highly cancer-specific antigens derived from somatic mutations, the so-called neoantigens, occurring in individual cancers have been in focus recently. Cancer immunotherapies, which target neoantigens, could lead to a precise treatment for cancer patients, despite the challenge in accurately predicting neoantigens that can induce cytotoxic T cells in individual patients. Precise prediction of neoantigens should accelerate the development of personalized immunotherapy including cancer vaccines and T-cell receptor-engineered T-cell therapy for a broader range of cancer patients. |
| format |
article |
| author |
Kazuma Kiyotani Yujiro Toyoshima Yusuke Nakamura |
| author_facet |
Kazuma Kiyotani Yujiro Toyoshima Yusuke Nakamura |
| author_sort |
Kazuma Kiyotani |
| title |
Personalized immunotherapy in cancer precision medicine |
| title_short |
Personalized immunotherapy in cancer precision medicine |
| title_full |
Personalized immunotherapy in cancer precision medicine |
| title_fullStr |
Personalized immunotherapy in cancer precision medicine |
| title_full_unstemmed |
Personalized immunotherapy in cancer precision medicine |
| title_sort |
personalized immunotherapy in cancer precision medicine |
| publisher |
China Anti-Cancer Association |
| publishDate |
2021 |
| url |
https://doaj.org/article/2d8dff79209e45a3b7ae968557deba2c |
| work_keys_str_mv |
AT kazumakiyotani personalizedimmunotherapyincancerprecisionmedicine AT yujirotoyoshima personalizedimmunotherapyincancerprecisionmedicine AT yusukenakamura personalizedimmunotherapyincancerprecisionmedicine |
| _version_ |
1718406611806978048 |